The real reason Elon is fully endorsing Trump

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump.

Watch this new documentary and you’ll discover what Elon knows,

Anthony Hunt Biography and Net Worth

CEO of Repligen

Tony J. Hunt was named President and CEO and has served on the Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board his deep understanding of the bioprocessing market.

What is Anthony Hunt's net worth?: The estimated net worth of Anthony Hunt is at least $18.86 million as of September 10th, 2024. Mr. Hunt owns 139,840 shares of Repligen stock worth more than $18,860,221 as of October 30th. This net worth approximation does not reflect any other investments that Mr. Hunt may own. Additionally, Mr. Hunt receives an annual salary of $885,000.00 as CEO at Repligen. Learn More about Anthony Hunt's net worth.
How old is Anthony Hunt?: Mr. Hunt is currently 60 years old. There are 3 older executives and no younger executives at Repligen. The oldest executive at Repligen is Mr. Ralf Kuriyel, Senior Vice President of Research & Development, who is 66 years old. Learn More on Anthony Hunt's age.
What is Anthony Hunt's salary?: As the CEO of Repligen Co., Mr. Hunt earns $885,000.00 per year. The highest earning executive at Repligen is Mr. Olivier Loeillot, President, CEO & Director, who commands a salary of $1,490,000.00 per year. Learn More on Anthony Hunt's salary.
How do I contact Anthony Hunt?: The corporate mailing address for Mr. Hunt and other Repligen executives is 41 SEYON STREET BUILDING 1 SUITE 100, WALTHAM MA, 02453. Repligen can also be reached via phone at (781) 250-0111 and via email at [email protected]. Learn More on Anthony Hunt's contact information.
Has Anthony Hunt been buying or selling shares of Repligen?: Anthony Hunt has not been actively trading shares of Repligen over the course of the past ninety days. Most recently, Anthony Hunt sold 22,191 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a transaction totalling $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company's stock, valued at $20,328,540.80. Learn More on Anthony Hunt's trading history.
Who are Repligen's active insiders?: Repligen's insider roster includes Nicolas Barthelemy (Director), James Bylund (SVP), Karen Dawes (Director), Carrie Eglinton Manner (Director), Christine Gebski (Insider), Anthony Hunt (CEO), Ralf Kuriyel (VP), Martin Madaus (Director), Thomas Ryan, Jr. (Director), and Jon Snodgres (CFO). Learn More on Repligen's active insiders.
Are insiders buying or selling shares of Repligen?: In the last year, Repligen insiders bought shares 2 times. They purchased a total of 3,615 shares worth more than $449,938.10. In the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 76,113 shares worth more than $12,939,797.71. The most recent insider tranaction occured on September, 10th when Director Anthony Hunt sold 22,191 shares worth more than $3,225,905.67. Insiders at Repligen own 1.2% of the company. Learn More about insider trades at Repligen.
Information on this page was last updated on 9/10/2024.

Anthony Hunt Insider Trading History at Repligen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/10/2024	Sell	22,191	$145.37	$3,225,905.67	139,840
6/14/2024	Buy	2,000	$124.08	$248,160.00	165,177
5/21/2024	Sell	20,072	$168.26	$3,377,314.72	163,177
3/8/2024	Sell	16,707	$197.44	$3,298,630.08	185,249
11/11/2022	Sell	25,000	$200.00	$5,000,000.00	178,265
9/8/2022	Sell	26,402	$224.73	$5,933,321.46	178,265
7/21/2022	Sell	24,802	$200.00	$4,960,400.00	194,667
11/18/2021	Sell	17,355	$276.85	$4,804,731.75
9/9/2021	Sell	25,000	$294.75	$7,368,750.00	214,495
5/19/2021	Sell	22,267	$171.41	$3,816,786.47	212,150
3/12/2021	Sell	9,102	$190.38	$1,732,838.76	220,950
3/4/2021	Sell	21,900	$190.19	$4,165,161.00	242,970
11/19/2020	Sell	20,000	$185.80	$3,716,000.00	253,327
9/10/2020	Sell	45,351	$148.20	$6,721,018.20	278,678
5/21/2020	Sell	46,953	$139.77	$6,562,620.81	238,157
3/3/2020	Sell	2,190	$88.22	$193,201.80	242,641
2/25/2020	Sell	11,735	$91.56	$1,074,456.60	231,148
9/19/2019	Sell	3,600	$82.89	$298,404.00	223,013
9/9/2019	Sell	12,094	$82.40	$996,545.60	210,976
3/18/2019	Sell	14,550	$59.63	$867,616.50	219,616
3/5/2019	Sell	13,000	$58.50	$760,500.00	229,657
2/28/2019	Sell	7,475	$59.01	$441,099.75	250,132
9/10/2018	Sell	27,566	$57.71	$1,590,833.86	255,017
5/21/2018	Sell	16,249	$42.53	$691,069.97	243,144
1/22/2018	Sell	8,970	$35.95	$322,471.50	83,613
11/28/2016	Sell	5,000	$33.12	$165,600.00	68,342

Anthony Hunt Buying and Selling Activity at Repligen

Repligen Company Overview

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $138.35

$133.56

$138.68

50 Day Range

MA: $142.81

$134.49

$152.95

2 Week Range

Now: $138.35

$113.50

$211.13

Volume

107,050 shs

Average Volume

659,872 shs

Market Capitalization

$7.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

The real reason Elon is fully endorsing Trump

From Porter & Company | Ad

Watch this new documentary and you’ll discover what Elon knows,

Anthony Hunt Biography and Net Worth

What is Anthony Hunt's net worth?

How old is Anthony Hunt?

What is Anthony Hunt's salary?

How do I contact Anthony Hunt?

Has Anthony Hunt been buying or selling shares of Repligen?

Who are Repligen's active insiders?

Are insiders buying or selling shares of Repligen?